Cytokine profile in drug-naïve panic disorder patients.
Laiana A Quagliato, Antonio E Nardi
https://pubmed.ncbi.nlm.nih.gov/35194013Actively Recruiting
Age: 18Years - 65Years
All Genders
Healthy Volunteers
ID07444879
Investigation of IL-33, sST2, and C-Reactive Protein in Panic Disorder: A Cross-Sectional Case-Control Study
Led by Elazığ Mental Health and Diseases Hospital · Updated on 2026-03-04
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating panic disorder (PD), a condition marked by unexpected panic attacks and significant challenges in daily functioning. This study focuses on exploring inflammatory processes in PD by measuring blood levels of interleukin-33 (IL-33), soluble suppressor tumorogenicity-2 (sST2), and C-reactive protein (CRP), which have not been studied before in this context. The goal is to better understand the role of inflammation in PD compared to healthy individuals. This observational case-control study involves two groups: adults aged 18 to 65 diagnosed with PD who have not used psychiatric medications, and healthy adults without psychiatric disorders. Participants will complete questionnaires and clinical scales, and provide fasting blood samples collected in the morning for measurement of IL-33, sST2, CRP, and blood counts. The study does not involve any treatment or intervention. Participants will provide demographic and clinical information and complete the DSM-5 Panic Disorder Severity Scale. Blood samples will be analyzed for inflammatory markers. Researchers will use statistical tests to compare groups and explore relationships between inflammation and panic disorder severity. The study is planned to include 40 participants and will take place at a mental health hospital, with participation lasting a single visit for data collection.
CONDITIONS
Brief Title
IL-33, sST2, and CRP in Panic Disorder
Who Can Participate
Age: 18Years - 65Years
All Genders
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
- Be between 18 and 65 years old
- Have a diagnosis of panic disorder according to DSM-5-TR and present with panic attack symptoms
- Have never used psychiatric medications (drug-naive)
- Have no other active psychiatric disorders besides panic disorder
- Have no hypertension, diabetes, kidney or liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Have not taken any medication or supplements in the last month
- Complete all sociodemographic and scale data fully
- Volunteer to participate in the study
You will not qualify if you...
- Be outside the 18 to 65 years age range
- Not meet the diagnostic criteria for panic disorder or be in good health
- Have a history of psychiatric medication use
- Have any other psychiatric disorder besides panic disorder
- Have hypertension, diabetes, kidney or liver failure, neurological disease with cognitive impairment, acute infection, pregnancy, autoimmune disease, or cancer
- Have a body mass index (BMI) less than 18.5 or greater than 29.9 kg/m²
- Have taken any medication or supplement in the last month
- Incomplete sociodemographic or scale data
- Not volunteer to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person) for eligibility assessment and consent
Diagnostic Evaluation
Duration - 1 day
Participants complete sociodemographic and clinical assessments including the DSM-5 Panic Disorder Severity Scale (Adult Form). Venous blood samples are collected after fasting to measure IL-33, sST2, and CRP levels.
1 baseline visit (in-person) including clinical assessments and blood draw
Trial Site Locations
Total: 1 location
1
Elazığ Mental Health and Diseases Hospital Psychiatry Clinic
Elâzığ, Elâzığ, Turkey (Türkiye), 23200
Actively Recruiting
Loading map...
Research Team
M
Mehmet Hamdi ÖRÜM, MD, Ass. Prof., Psychiatrist
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status.
Izabela Guimaraes Barbosa, Isabela Boechat Morato, Aline Silva de Miranda...
https://pubmed.ncbi.nlm.nih.gov/24581826Alterations in Peripheral C-Reactive Protein and Inflammatory Cytokine Levels in Patients with Panic Disorder: A Systematic Review and Meta-Analysis.
Chang-He Liu, Na Hua, Huai-Yu Yang
https://pubmed.ncbi.nlm.nih.gov/34908836Pro-inflammatory cytokines and soluble receptors in response to acute psychosocial stress: differential reactivity in bipolar disorder.
Andrea Wieck, Rodrigo Grassi-Oliveira, Carine Hartmann do Prado...
https://pubmed.ncbi.nlm.nih.gov/25092610Differences in the immune-inflammatory profiles of unipolar and bipolar depression.
Andre R Brunoni, Thitiporn Supasitthumrong, Antonio Lucio Teixeira...
https://pubmed.ncbi.nlm.nih.gov/31693974Panic disorder.
Lara J Hoppe, Jonathan Ipser, Jack M Gorman...
https://pubmed.ncbi.nlm.nih.gov/22608631